Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-217,014 in Irritable Bowel Syndrome
NCT00139672Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing PD-217,014 with Placebo (2 arms). Primary endpoint: Relief of abdominal pain/discomfort responder rate at 4 weeks. Started Jan 2004; status: completed.
02
Drugs
PD-217014
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00139672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00139672.